These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32264820)

  • 1. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.
    Ornello R; Casalena A; Frattale I; Gabriele A; Affaitati G; Giamberardino MA; Assetta M; Maddestra M; Marzoli F; Viola S; Cerone D; Marini C; Pistoia F; Sacco S
    J Headache Pain; 2020 Apr; 21(1):32. PubMed ID: 32264820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
    Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON).
    Göbel H; Schlegel E; Jaeger K; Ortler S; Leist L
    J Headache Pain; 2024 Sep; 25(1):157. PubMed ID: 39322961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study.
    Lanteri-Minet M; Fabre R; Martin C; Pradat K; Alchaar A; Bozzolo E; Duchene ML; Van Obberghen EK; Donnet A; Fontaine D
    J Headache Pain; 2023 Nov; 24(1):152. PubMed ID: 37940860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region.
    Ornello R; Casalena A; Frattale I; Caponnetto V; Gabriele A; Affaitati G; Giamberardino MA; Assetta M; Maddestra M; Marzoli F; Viola S; Cerone D; Marini C; Pistoia F; Sacco S
    J Headache Pain; 2020 Aug; 21(1):102. PubMed ID: 32799790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
    Tepper SJ; Diener HC; Ashina M; Brandes JL; Friedman DI; Reuter U; Cheng S; Nilsen J; Leonardi DK; Lenz RA; Mikol DD
    Neurology; 2019 May; 92(20):e2309-e2320. PubMed ID: 30996056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal.
    Ornello R; Tiseo C; Frattale I; Perrotta G; Marini C; Pistoia F; Sacco S
    J Headache Pain; 2019 Oct; 20(1):99. PubMed ID: 31666008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective real-world analysis of erenumab in refractory chronic migraine.
    Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
    J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
    Reuter U; Goadsby PJ; Ferrari MD; Da Silva Lima GP; Mondal S; Kalim J; Hasan F; Wen S; Arkuszewski M; Pandhi S; Stites T; Lanteri-Minet M
    Neurology; 2024 May; 102(10):e209349. PubMed ID: 38669638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.
    Eghtesadi M; Leroux E; Pagé G
    Clin Drug Investig; 2021 Aug; 41(8):733-739. PubMed ID: 34287786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
    Tepper SJ; Lipton RB; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Wang A; Cheng S; Klatt J; Mikol DD
    Headache; 2023 Jun; 63(6):730-742. PubMed ID: 37313616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
    Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
    JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
    Cullum CK; Do TP; Ashina M; Bendtsen L; Hugger SS; Iljazi A; Gusatovic J; Snellman J; Lopez-Lopez C; Ashina H; Amin FM
    J Headache Pain; 2022 Jun; 23(1):61. PubMed ID: 35655137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
    Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
    Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology].
    Dobrynina LA; Gubanova MV; Belopasova AV; Baydina EV; Afanasev MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(2):74-80. PubMed ID: 35271240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
    Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
    BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
    Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.